CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV - News) announced that it has completed patient enrollment in the second of two US pivotal Phase 3 studies for its injectable pain drug, Dyloject(TM) (diclofenac sodium). This pivotal clinical study evaluated Dyloject in patients with moderate-to-severe postoperative pain following elective orthopedic surgery. A previously completed and successful US pivotal study evaluated Dyloject in patients suffering from moderate-to-severe postoperative pain after elective abdominal surgery. The Company is planning to file a New Drug Application for the treatment of acute postoperative pain in 2009.
